Company Profile
Medtide Inc., a contract research, development, and manufacturing company provides early-stage discovery, pre-clinical research, clinical development, and commercial-stage production services.
It offers peptide new chemical entity discovery synthesis, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products.
Its R&D technology platforms include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening. The company serves customers in China, the United States, Japan, Europe, South Korea, and Australia. Incorporated in 2020 and headquartered in Hangzhou, China, Medtide was formerly known as Taide Pharmaceutical (Zhejiang) Co., Ltd before rebranding in February 2023.